INFERGEN INJECTION

<table>
<thead>
<tr>
<th>Brand Name</th>
<th>Generic Name</th>
<th>Length of Authorization</th>
</tr>
</thead>
<tbody>
<tr>
<td>Infergen Injection</td>
<td>interferon alfacon-1</td>
<td>Per Medical Guidelines</td>
</tr>
</tbody>
</table>

Approvable Criteria:
1. The member is 18 years of age or older, **AND**
2. Infergen is used in combination with ribavirin for the treatment of *chronic Hepatitis C infection* in members with compensated liver disease who have anti-HCV serum antibodies and/or the presence of HCV RNA or Hepatitis C virus (use of monotherapy with an interferon product is not recommended unless a member is unable to take ribavirin), **AND**
3. The member has tried and failed a pegylated interferon and ribavirin combination

Approvable Duration:
- Treatment of Hepatitis C Genotype 2 or 3: 24 weeks
- Treatment of Hepatitis C Genotype 1: Up to 48 weeks

**QL= 30 vials x 30 DAYS**
**SELF-ADMINISTERED – RX ONLY**
**SPECIALTY PHARMACY PRODUCT**

**FDA Recommended Dose:**
**Monotherapy:**
9 mcg 3 times a week administered SC as a single injection for 24 weeks. At least 48 hours should elapse between doses of interferon alfacon-1.
Patients who tolerated previous interferon therapy and did not respond or relapsed following its discontinuation may be subsequently treated with 15 mcg of interferon alfacon-1 three times a week administered subcutaneously as a single injection for up to 48 weeks (see illustrated Medication Guide for instructions).

**In Combination with Ribavirin:**
15mcg SC daily; use in combination with weight-based ribavirin (1000mg/day PO for patients < 75kg and 1200mg/day PO for patient ≥ 75kg) administered in 2 divided doses each day. Give the combination for up to 48 weeks.

*There are significant differences in specific activities among interferons. Health care practitioners should be aware that changes in interferon brand may require adjustments of dosage or change in route of administration. Patients should be warned not to change brands of interferon without medical consultation. Patients should also be instructed by their physician not to reduce the dosage of interferon alfacon-1 prior to medical consultation.*

**References:**